## នុី FBP1/FBPase 1 (D1B6A) Rabbit mAb





Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity: H	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 39	<b>Source/Isotype:</b> Rabbit IgG	<b>UniProt ID:</b> #P09467	Entrez-Gene Id: 2203		
Product Usage Information		<b>Application</b> Western Blotting			Dilution 1:1000			
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.						
Specificity/Sen	sitivity	FBP1/FBPase 1 (D1B6A) Rabbit mAb recognizes endogenous levels of total FBP1/FBPase 1 protein.						
Source / Purific	ation	Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human FBP1/FBPase 1 protein.						
Background		Fructose-1,6-bisphosphatase 1 (FBP1 or FBPase 1), a rate limiting enzyme in gluconeogenesis, catalyzes the conversion of fructose-1,6-bisphosphate to fructose-6-phosphate (1). Inhibition of <i>FBP1</i> expression in basal-like breast cancer (BLBC) cells leads to metabolic reprogramming, including enhanced glycolysis, which leads to increased glucose uptake, biosynthesis of macromolecules, and activation of PKM2 (1). This metabolic reprogramming endows tumor cells with cancer stem cell (CSC)-like properties, thereby increasing their tumorigenicity (1). Depletion of FBP1 was also reported in more than 600 clear cell renal cell carcinoma (ccRCC) tumors, suggesting that FBP1 may inhibit ccRCC tumor progression (2).						
Background Re	ferences	1. Dong, C. et al. (2013) <i>Cancer Cell</i> 23, 316-31. 2. Li, B. et al. (2014) <i>Nature</i> 513, 251-5.						
Species Reactiv	vity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).						
Western Blot B	uffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.						
Applications Ke	ey	W: Western Blotting						
Cross-Reactivit	у Кеу	H: Human						
Trademarks an	d Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.						
		All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.						
Limited Uses		Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.						
		approved, cleared, or purpose. Customer sh any manner that conf Customer as the end- diagnostic, prophylact component) or other sell, license, loan, don whether alone or in co	licensed by the FDA hall not use any Pro licts with its labelin user and solely for tic or therapeutic pro commercial purpos ate or otherwise tra combination with otl	se Only or a similar labe or other regulatory for duct for any diagnostic of g statement. Products so research and developme urposes, or any purchas e, requires a separate li ansfer or make available her materials, or use the y, reverse engineer, deco	eign or domestic en or therapeutic purp- old or licensed by CS ent uses. Any use of e of Product for res- cense from CST. Cus e any Product to any Products to manuf	itity, for any ose, or otherwise in ST are provided for Product for ale (alone or as a tomer shall (a) not third party, acture any		

attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.